Skip to main content
. Author manuscript; available in PMC: 2018 Jul 28.
Published in final edited form as: Cancer Lett. 2017 Apr 12;399:29–43. doi: 10.1016/j.canlet.2017.04.005

Figure 1. IFITM1 overexpression is associated with aromatase inhibitor-resistant breast cancer cells and correlates with poor clinical outcome.

Figure 1

(a) Whole cell lysates from 80% confluent MCF-7 and MCF-7:5C cells were immunoblotted for IFITM1 and ERα protein expression. (b) IFITM1 and ERα mRNA expression was determined by RT-PCR and is displayed relative to PUM1. Data represents three independent experiments run in triplicate. (c) The hazard ratio (HR) and 95 % confidence interval for high IFITM1 expression in ER+ Luminal A breast cancer patients was analyzed using The Kaplan-Meier Plotter database. Patients were stratified by average IFITM1 expression (probe sets 214022_s_at and 201601_x_at) relative to median. The P-value was calculated using a log-rank test. (d) Immunohistochemical staining for IFITM1 expression was conducted in 94 ER+ breast cancer patient samples and 6 normal breast tissue samples. Staining intensity was graded on a scale of 0–3. IFITM1 staining intensity was correlated with clinical stage (d) and recurrence (e). *p < 0.05, ** p< 0.01